title: Comparison of long-term effect of dual-chamber pacing and alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
abstract: BACKGROUND
  Nonpharmacological treatment of patients with hypertrophic obstructive cardiomyopathy (HOCM) comprises surgical myectomy (SME), alcohol septal ablation (ASA), and dual-chamber (DDD) pacing. The aim of the study was to compare the long-term effect of DDD pacing and ASA in symptomatic HOCM patients.
  
  
  METHODS
  We evaluated retrospective data from three cardiocenters; there were 24 patients treated with DDD pacing included and 52 treated with ASA followed for 101 ± 49 and 87 ± 23 months, respectively.
  
  
  RESULTS
  In the group treated with DDD pacing, the left ventricle outflow tract gradient (LVOTG) decreased from 82 ± 44 mmHg to 21 ± 21 mmHg, and NYHA class improved from 2.7 ± 0.5 to 2.1 ± 0.6 (both P < 0.001). In the ASA-treated group, a decline in LVOTG from 73 ± 38 mmHg to 24 ± 26 mmHg and reduction in NYHA class from 2.8 ± 0.5 to 1.7 ± 0.8 were observed (both P < 0.001). The LVOTG change was similar in both groups (P = 0.264), and symptoms were more affected by ASA (P = 0.001).
  
  
  CONCLUSIONS
  ASA and DDD pacing were similarly effective in reducing LVOTG. The symptoms improvement was more expressed in patients treated with ASA.
authors: Department of Cardiovascular Diseases, St. Anne's University Hospital-International Clinical Research Center and Masaryk University, Pekařská 53, 656 91 Brno, Czech Republic.
authors: Jan
authors: J
authors: Krejci
authors: Pavel
authors: P
authors: Gregor
authors: David
authors: D
authors: Zemanek
authors: Klaudia
authors: K
authors: Vyskocilova
authors: Karol
authors: K
authors: Curila
authors: Radka
authors: R
authors: Stepanova
authors: Miroslav
authors: M
authors: Novak
authors: Ladislav
authors: L
authors: Groch
authors: Josef
authors: J
authors: Veselka
mesh_terms: D058406:Cardiac Resynchronization Therapy / Q000379:methods*; D002312:Cardiomyopathy, Hypertrophic / Q000000981:diagnostic imaging* / Q000628:therapy*; D003131:Combined Modality Therapy; D018153:Czech Republic; D004452:Echocardiography; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000627:therapeutic use; D015911:Sclerotherapy; D016896:Treatment Outcome
chemical_list: D012597:Sclerosing Solutions; D000431:Ethanol